US equities |
SPCX $166.91 ▲+5.00% NVDA $236.75 ▲+1.20% MU $1,064.29 ▼-0.99% TSLA $377.13 ▲+1.77% MSFT $526.50 ▲+1.73% SNDK $1,714.50 ▼-0.32% INTC $117.33 ▼-1.68% META $744.25 ▲+2.22%
FinancialContent

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

4.945 -0.195 (-3.79%)
Delayed Quote Updated: 11:57 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Nuvation Bio (NUVB) Q2 2026 Earnings Call Transcript ↗
IBTROZI revenue hit $23.2 million with 85% of new patient starts in first-line setting. 
Via The Motley Fool
Topics Earnings
News headline image
Nuvation Bio Q2 Earnings Call Highlights ↗
Nuvation Bio (NYSE:NUVB) reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung... 
Via MarketBeat
Topics Earnings
News headline image
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale? ↗
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development. 
Via The Motley Fool
Topics Regulatory Compliance
Nuvation Bio (NYSE:NUVB) Soars 22% After Earnings Beat Fueled by Strong Lung Cancer Drug Launch ↗
Via Chartmill
Topics Earnings
NUVATION BIO INC (NYSE:NUVB) Stock Plunges 9% After Q4 Earnings Reveal Revenue Beat but Wider Loss ↗
Via Chartmill
Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut ↗
Via Stocktwits
News headline image
Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum ↗
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nuvation Bio (NUVB) Q1 2026 Earnings Transcript ↗
Nuvation Bio (NUVB) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB) ↗
This oncology-focused biotech, advancing multiple clinical-stage therapeutics, just reported a notable insider sale in recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
From Pomerantz LLP
Via GlobeNewswire
News headline image
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗
This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers. 
Via The Motley Fool
Topics Regulatory Compliance
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript ↗
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
From Nuvation Bio and Eisai
Via Business Wire
News headline image
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025... 
Via MarketMinute
News headline image
Which stocks are moving on Wednesday? ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >